Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany

• Published in: BMC cancer 2019-05, Vol.19 (1), p.520-14, Article 520
• Main Authors: Holleczek, Bernd, Stegmaier, Christa, Radosa, Julia C, Solomayer, Erich-Franz, Brenner, Hermann
• Format: Article
• Language: English
• Subjects: Age; Analysis; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - pathology; Cancer metastasis; Cancer recurrence; Cancer registry; Cancer research; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Cumulative incidence; Diagnosis; Distant metastases; ErbB-2 protein; Female; Germany - epidemiology; Humans; Incidence; Invasive breast cancer; Invasiveness; Loco-regional recurrence; Lymphatic system; Mastectomy; Medical prognosis; Metastases; Metastasis; Mortality; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pathology; Patients; Population; Population studies; Population-based; Population-based studies; Practice guidelines (Medicine); Prognosis; Quality of life; Radiation therapy; Recurrence (Disease); Registries - statistics & numerical data; Risk Factors; Studies; Surgery; Tumors; Women's health
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-5710-5

Population-based estimates of the long-term risk of loco-regional recurrence and distant metastases of breast cancer (BRC) patients are scant, as most published studies used hospital-based cohorts or participants of clinical trials. This work aims to extend available knowledge by providing population-based long-term estimates of the cumulative risk of BRC recurrence up to 10 years after diagnosis. Data from the population-based Saarland Cancer Registry were used and included 9359 female patients with primary invasive BRC diagnosed between 1999 and 2009. Estimates of the cumulative incidence (CI) of BRC recurrence were derived for patients who had received local surgery with free resection margins by type of recurrence and stratified by age, tumor characteristics and major treatment options, taking into account mortality from any cause as a competing risk. The 10-year CI of BRC recurrence was 16%. For loco-regional recurrence and distant metastases alone it was 8 and 11%, respectively. The estimates showed substantial variation and were particularly increased if tumors were advanced (T1/2N+ 23%, T3/4N0 24%, T3/4N+ 34%), of high grade (23%), or of 'HER2/neu positive' (28%) or 'triple negative' subtype (23%), respectively. The derived estimates reflect the risk of 'real world' patients and may therefore extend available knowledge. These data are thus of great relevance for clinicians, their patients and researchers. The study likewise demonstrated the usefulness of cancer registries for a population-based monitoring of the effectiveness of cancer care in terms of disease recurrence as a major treatment related outcome measure.